December 7, 2017 09:43 AM EST
News Briefing

Canada's AmorChem launch­es $44.2M life sci­ence fund; Neon adds $36M, Mer­ck part­ner­ship in neoanti­gen dri­ve; CRISPR Ther­a­peu­tics files a CTA

Brittany Meiling

→ Cana­di­an VC firm AmorChem Group has raised $44.2 mil­lion for its sec­ond life sci­ence fund. Backed by LPs in­clud­ing the Québec gov­ern­ment, Mon­tre­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times